Masterclass
Our TMS Masterclass & Certification course takes you from the basics of TMS and Brain Stimulation, to exciting new developments in this field with world renown speakers from all over the...
Resources
Get access to our Brainclinics resources, such as books, theses and the open access TDBRAIN EEG dataset with more than 1200 EEG’s and descriptive data.
News
We regularly post news on Linkedin. Please follow us on Linkedin to get the latest news in your Linkedin feed.
Screen use 2 hours before bedtime had no effect on total sleep duration, but it did delay sleep onset by an average of 10 minutes, with interactive screen use in bed being more harmful for sleep compared to passive screen use.
With the growing prevalence of screen use among adolescents, especially before bedtime, its potential impact on sleep health has garnered increased attention. A recent study published in JAMA Pediatrics explored the associ...
Net uit in TvP: De toepassing van rTMS bij dwangstoornissen in Nederland en België: consensusverklaring
Bij dwangstoornissen (OCS) die niet voldoende reageren op gedragstherapie of medicatie was het enige (vergoede) alternatief diepe hersenstimulatie (DBS). In deze consensusverklaring adviseren we niet-invasieve hersenstimulatie (TMS) te overwegen voordat bij iemand DBS geïndiceerd is.
https://lnkd.in/eEMRZfBh
Congrats: Odile A. van den Heuvel...
Just out in AJP: rTMS as a Next Step in Antidepressant Nonresponders: A Randomized Comparison With Current Antidepressant Treatment Approaches.
TMS was 5.5X more likely to result in remission relative to the next medication step after 2 failed treatments (27 vs 5% remission). Why even consider a third medication step?
Congrats Iris Dalhuisen, Philip van Eijndhoven, Indira Tendolkar and colleagues for a great study.
https://lnkd.in/g_us64aQ
June 25th Helena Voetterl succesfully defended her PhD titled: Biomarkers from Bench to Bedside: Realizing a future of EEG-Based Stratified Psychiatry. Congrats Helena Voetterl!
In her PhD she developed and clinically validated an EEG biomarker - called Brainmarker-I - as a biomarker to stratify ADHD or Depressed patients between various evidence based treatments, resulting in higher remission rates. This has become a great piece of work, with ...
Join me in celebrating 100 years of EEG, please reshare!
On July 6th, 1924 Hans Berger recorded the first EEG on a human, only published in 1929. This invention of the EEG has resulted in many clinical applications ranging from diagnosing epilepsy and sleep disorders to Brain Machine Interfaces (BMI/BCI), neurofeedback and EEG as the first clinically actionable biomarker in precision and stratified psychiatry.
What's your favorite application ...
Last week Hannah Meijs succesfully defended her PhD titled: Decoding Complexity: A data-driven approach to unraveling transdiagnostic markers in psychiatry. Congrats Hannah Meijs!
This has become a great piece of work, probably including the largest amount of EEG data ever in a PhD, exceeding >7.5K unique EEG's and sophisticated analyses applied, including fICA LORETA and AI/Deep Learning.
The PhD thesis is available for download here: https://l...
Sleep problems are present in many psychiatric disorders. We recently reported the presence of sleep problems resulted in worse response to TMS in OCD (Gajadien et al 2023). Here we asked the question if the presence of a sleep disorder predicts worse response to DLPFC TMS in Depression using a specific sleep disorder questionnaire.
Using two large samples (N=299) we did not find differential response related to the presence of a sleep disorder....
Glad to see this published: Challenging the Diagnostic Value of Theta/Beta Ratio: Insights From an EEG Subtyping Meta‑Analytical Approach in ADHD
Article can be downloaded here: https://rdcu.be/dKrzG
And for clinicians we released a free to use TBR calculator powered by the TDBRAIN+ database: Input age, sex, and log(TBR) and voila, an individualised comparison of TBR to decide between SMR vs TBR neurofeedback: https://lnkd.in/eWmbFP-e
Congrats...
FDA Advisory Panel votes against Lykos/MAPS MDMA-Assisted therapy both on efficacy and risks. More homework needed in psychedelics trials: Better blinding required, preventing selection bias and mitigating risks for abuse. Maybe a role for AI-based tools in the assisted therapy part?
Read more: https://lnkd.in/efr-Mx2q